Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Hypersensitivity to CPA or any of the other components of the medication Pregnancy, lactation, and breastfeeding Puberty (except if being used to treat precocious puberty or delay puberty) Liver diseases and liver dysfunction Chronic kidney disease Dubin–Johnson syndrome and Rotor syndrome History of jaundice or persistent pruritus during pregnancy History of herpes during pregnancy Previous or existing liver tumors (only if not due to metastases from prostate cancer) Previous or existing meningioma, hyperprolactinemia, or prolactinoma Wasting syndromes (except in inoperable prostate cancer) Severe depression Previous or existing thromboembolic processes, as well as stroke and myocardial infarction Severe diabetes with vascular changes Sickle-cell anemia When CPA is used in combination with an estrogen, contraindications for birth control pills should also be considered.
== Importance == D. dadantii has been associated with bacterial soft rot diseases of a majority of foliage plants, numerous flowering plants and many vegetables. It is a major pathogen for many economic crops such as potatoes, banana and pineapple in addition to ornamental house plants. It causes blackleg of potato. In addition to the pathogen having important negative consequences, D. dadantii is being used for its positive contributions. Most noble of its contributions is an enzyme, asparaginase, being used in conjunction with other chemotherapeutic agents for treatment of acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma in patients who have had allergic reactions to E. coli derived asparaginase Elspar or pegaspargase (Oncaspar). Secondly, with a strong governmental push towards increasing renewable fuel resources, D. dadantii is being studied for its utilization in ethanol fuel production and its ability to ferment and break down cell walls and pectins as an alternative to E. coli. Although not as effective as D. dadantii, some genes from D. dadantii were added to E. coli through genetic engineering to allow for pectin degradation by E. coli.
H2SO4 + CH3CO2Na → NaHSO4 + CH3COOH Similarly, treating potassium nitrate with sulfuric acid produces nitric acid. Sulfuric acid reacts with sodium chloride, and gives hydrogen chloride gas and sodium bisulfate:
Sources: en.wikipedia.org
A type of study in which both the health providers and the patients are aware of the drug or treatment being given. (NCI) A clinical trial in which doctors and participants know which drug or vaccine is being administered. (NLM) Orphan drugs
=== Twitter defamation case === In April 2022, Galloway's Twitter account was labelled "Russian state-affiliated media" by Twitter. In response Galloway tweeted: "I work for NO Russian media. I have 400,000 followers. I'm the leader of a British political party and spent nearly 30 years in the British parliament. If you do not remove this designation I will take legal action." Twitter users pointed out that Galloway's profile named the Russian state media outlets that he worked for. Galloway then removed these from his profile. He said Twitter had refused to explain the label, which he said was added to his account after he had stopped presenting on Russian television channels, which were closed by the British government in March 2022. Galloway sued Twitter for defamation in the High Court, Dublin. The suit also alleged that Twitter had unlawfully processed his personal data by labelling and censoring his account. In October 2024, the High Court in Dublin ordered Twitter to pay Galloway's legal costs. It also ordered both parties to "submit sworn affidavits attesting to the truth of their claims" by 30 January 2025.
Hypervitaminosis A results from excessive intake of preformed vitamin A. Genetic variations in tolerance to vitamin A intake may occur, so the toxic dose will not be the same for everyone. Children are particularly sensitive to vitamin A, with daily intakes of 1500 IU/kg body weight reportedly leading to toxicity.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.